Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19

This is an investigator initiated, open label, multicenter, two arm, randomized study to compare the impact of adding IVIG to the Standard of Care (SOC) to the SOC without IVIG. Randomization will be 1:1. The goal of this study is to identify whether or not IVIG can halt the progression to respiratory failure requiring mechanical ventilation in subjects admitted to the hospital with confirmed COVID-19. The addition of IVIG to the standard of care treatment for these patients may be beneficial in abating acute lung injury in subjects with SARSCoV-2 induced hypoxia that results in organ injury.

Inclusion criteria

• Confirmed COVID-19 positive test result (including presumptive positive).
• Hospitalization
• Requiring ≥4 liters/min O2 nasal cannula to maintain oxygen saturation ≥ 92%, but not mechanically ventilated
• Age ≥18 years old.
• Access to a phone in the hospital room or an electronic device that is capable of receiving phone calls and/or video calls and/or e-mail.
• Able to read/write/speak English or Spanish fluently.
• Subjects must have the capacity to provide consent or an appropriate Legally Authorized Representative (LAR) to provide informed consent.

provide informed consent, and provide authorization of use and disclosure of personal health information.

• Negative pregnancy test for women of childbearing potential.

Exclusion criteria

• Severe allergy to any IVIG product formulation
• History of DVT, PE, thromboembolic stroke or other thrombotic events
• Hypersensitivity to corn. Octagam® contains maltose which is a sugar derived from corn.
• Uncontrolled hypertension (SBP>180 mm Hg or DBP>120mmHg)
• Active participant in another research treatment study
• Mechanically ventilated patient
• Code status is Do Not Resuscitate or Do Not Intubate